• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Evaluating Carbapenem Resistance

August 27, 2018
Rebecca A Packer, MS, DVM, DACVIM (Neurology/Neurosurgery)

A look at the current state of carbapenem resistance in nontyphoidal serovars of Salmonella enterica.

Nontyphoidal serovars of Salmonella enterica, which are responsible for a significant proportion of foodborne illnesses in humans and animals, are acquired most often through ingestion of contaminated meat, milk, and egg products. Although these organisms typically cause self-limiting gastroenteritis, they can result in serious systemic infections, particularly in children, the elderly, or immunocompromised individuals. In this patient population, antibiotic resistance is of serious concern and may have fatal consequences. In a recent review in Veterinary Science, investigators evaluated carbapenem resistance in nontyphoidal serovars of S enterica.

Carbapenem resistance has generally been rare in nontyphoidal S enterica infections. Recently, horizontal gene transfer has been identified as an important mechanism of resistance, as well as co- and cross-selection of resistance across other antimicrobial classes.

RELATED:

  • Antibiotic Resistance is a Global Threat
Advertisement
  • Innovative Strategies for Fighting Antimicrobial Resistance

Several mechanisms of resistance were described in human infections, but of most interest and concern, various carbapenemase-encoding genes that originally segregated according to geographic derivation, showed evidence of worldwide spread through colonization of nosocomial bacteria via horizontal gene transfer. This is of great concern given the abundance of nosocomial organisms in hospitals and other health facilities.

In veterinary livestock medicine, carbapenem-resistant nontyphoidal S enterica infections are present, despite the lack of use of carbapenems in livestock medicine, suggesting reservoirs other than human nosocomial infections. Co- and cross-selection from other classes of antimicrobials, in particular third-generation (eg, extended-spectrum) cephalosporins, is likely responsible for the transmission of carbapenem resistance in these cases. The abundant use of long-acting cephalosporins in companion animal medicine is likely contributing to this. Widespread use of carbapenems and third-generation cephalosporins where more narrow-spectrum antimicrobials are sufficient, is thought to be inappropriate and should be avoided. Global surveillance and legislation limiting the use of these antimicrobials is recommended to avoid further transmission of resistance. Such legislation already exists in the European Union.

Clinical Impact

Carbapenem resistance is a serious and worldwide public health concern, as carbapenem is a valuable “last resort” antimicrobial. To minimize further spread of carbapenem resistance, carbapenems, as well as extended-spectrum cephalosporins, particularly long-acting, third-generation cephalosporin formulations (eg, cefovecin and cefpodoxime), should be reserved for exceptional cases.

Dr. Packer, an associate professor of neurology/neurosurgery at Colorado State University College of Veterinary Medicine and Biomedical Sciences in Fort Collins, is board certified in neurology by the American College of Veterinary Internal Medicine. She is active in clinical and didactic training of veterinary students and residents and has developed a comparative neuro-oncology research program at Colorado State University.


Advertisement

Latest News

Four ways to curb no shows

FDA and European Union expand Mutual Recognition Agreement to include animal drugs

Successful tolerability study of CBD products for dogs

Second annual 'Dog Days of Summer' adoption event to take place in Michigan

View More Latest News
Advertisement